Trial Profile
A prospective, randomized, double blind, placebo controlled study of intravenously infused ZYKR1 to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2020
Price :
$35
*
At a glance
- Drugs ZYKR 1 (Primary)
- Indications Postoperative pain; Visceral pain
- Focus Adverse reactions
- Sponsors Zydus Lifesciences
- 19 May 2020 Status changed from recruiting to discontinued.
- 05 Nov 2019 Status changed from not yet recruiting to recruiting.
- 14 Nov 2018 New trial record